Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Over 72 hrs. eom

While I don't disagree with the historical account of the BOD's handling of the agreement, you have to agree that the structure in place will remain in place. Neither party has the funds to litigate the dissolution of the agreement. TPL appears to be in greater financial difficulty than PTSC. TPL in my judgement can do little to change the "game" until they receive money. I disagree with your thoughts on TPL's financial position. They rely on MMP revenues as does PTSC. They operate with greater overhead. I don't like the cash burn anymore than you at PTSC. I think TPL may be at greater risk. Neither of us know for sure because we do not have access to the information. What we do know is that TPL needed about two million from PTSC. It certainly has been easy to become jaded over the years with this company and the BOD's performance. One has to remember that "they" (BOD, TPL, Lawyers and us) all want money too. The way that meaningful dollars will be garnered is with the MMP. Everyone knows that. It does give me pause though that millions have been lost by poor choices made by this board. This has been a long road for many. There is plenty on blame to go around, including blaming ourselves. My focus is on what happens to the MMP in the courts, the remaining patents at the USPTO, and licenses sold. Paying attention to those areas will help me evaluate my course with this stock. All the best to you.

Share
New Message
Please login to post a reply